Buscar
Nutriband Inc
NTRBWAñadir a la lista de seguimiento
0.990USD
-0.110-10.00%
Cierre （ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Nutriband Inc Compañía
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Información de Nutriband Inc
Símbolo de cotizaciónNTRBW
Nombre de la empresaNutriband Inc
Fecha de salida a bolsaJun 20, 2017
Director ejecutivoMr. Serguei Melnik
Número de empleados- -
Tipo de seguridadCompany Warrant
Fin del año fiscal- -
Dirección121 S Orange Ave Ste 1500
CiudadORLANDO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal32801-3241
Teléfono14073776695
Sitio Webhttps://nutriband.com/
Símbolo de cotizaciónNTRBW
Fecha de salida a bolsaJun 20, 2017
Director ejecutivoMr. Serguei Melnik
Ejecutivos de Nutriband Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sergei Glinka
Mr. Sergei Glinka
Independent Director
Independent Director
--
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
--
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
--
--
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
--
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sergei Glinka
Mr. Sergei Glinka
Independent Director
Independent Director
--
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Nutriband Inc?
Los cinco principales accionistas de Nutriband Inc son: Mr. Sergei Glinka